
Protagonist Therapeutics (PTGX) Stock Forecast & Price Target
Protagonist Therapeutics (PTGX) Analyst Ratings
Bulls say
Protagonist Therapeutics Inc's increased enterprise value-to-sales (EV/Sales) multiple, rising from 8.0x to 9.5x, reflects strong anticipated growth driven by a favorable mix of milestone payments and royalties expected to generate high margins. The company has demonstrated significant efficacy in its pipeline, particularly with icotrokinra, which shows increased peak market penetration projections and potential revenue of $3.2 billion in psoriasis and $3 billion in ulcerative colitis. Furthermore, the prospect of additional revenue drivers from preclinical assets further enhances Protagonist's growth outlook, supporting a robust future market position.
Bears say
Protagonist Therapeutics Inc faces significant regulatory risks that may lead to delays or rejections in the approval processes of its pipeline products, thereby reducing potential future cash flows and negatively impacting share price. Additionally, the company is expected to continue incurring net losses until its products receive approval and enter the market, with anticipated capital raises posing a dilutive effect on shareholder value. The uncertainties surrounding product uptake, patient recruitment for trials, and negative policy developments further contribute to a negative outlook on the company’s financial health.
This aggregate rating is based on analysts' research of Protagonist Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Protagonist Therapeutics (PTGX) Analyst Forecast & Price Prediction
Start investing in Protagonist Therapeutics (PTGX)
Order type
Buy in
Order amount
Est. shares
0 shares